** Shares of drug developer Summit Therapeutics SMMT.O rise 6.2% to $23.50 premarket
** Co says it is collaborating with Pfizer PFE.N to study its experimental drug ivonescimab in combination with several of Pfizer's targeted cancer therapies called antibody drug conjugates (ADCs) across different types of tumors
** Under the agreement, SMMT will provide ivonescimab for the studies, which PFE will conduct
** Studies expected to start mid-year
** SMMT's drug has previously showed better survival rates in some lung cancer patients in a trial in China, outdoing Merck's MRK.N blockbuster Keytruda
** Stock has risen 5x in the last 12 months after outperforming Keytruda - the world's biggest drug with more than $29 billion in sales last year - in those studies
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。